Kiniksa Pharmaceuticals, Ltd.

General Information


We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. We have three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018.

Employees: 47
Founded: 2015
Contact Information
Address Clarendon House, 2 Church Street, Hamilton HM11, Bermuda
Phone Number (441) 295-5950
Web Address
View Prospectus: Kiniksa Pharmaceuticals, Ltd.
Financial Information
Market Cap $871.9mil
Revenues $0 mil (last 12 months)
Net Income $-75.9 mil (last 12 months)
IPO Profile
Symbol KNSA
Exchange NASDAQ
Shares (millions): 8.5
Price range $18.00 - $18.00
Est. $ Volume $152.6 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan
CO-Managers JMP Securities/ Wedbush PacGrow
Expected To Trade: 5/24/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change